Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA
RVMD•FDA accepts daraxonrasib application for review
July 22 (Reuters) - Revolution Medicines Inc RVMD.O:
- Revolution Medicines’ new drug application for daraxonrasib has been accepted for review by the U.S. FDA for previously treated metastatic pancreatic cancer.
